Letybo Phase 3 Data Show Rapid Improvement in Frown Lines at ASDS 2026
Key Takeaways
- Phase 3 BLESS III data presented at the 2026 American Society for Dermatologic Surgery (ASDS) Annual Meeting showed that 64.7% of patients treated with Letybo (letibotulinumtoxinA-wlbg) met the primary improvement endpoint at week 4, compared with 0% receiving placebo.
- The median time to improvement was 3 days, and no serious treatment-related adverse events were reported in the Phase 3 study.
- Additional analyses examined outcomes among women aged 35 to 50 years and patient-reported quality of life and satisfaction across three BLESS trials.

New Phase 3 clinical trial data presented at the 2026 American Society for Dermatologic Surgery (ASDS) Annual Meeting showed improvements in moderate to severe glabellar lines among patients treated with Letybo (letibotulinumtoxinA-wlbg), according to an announcement from manufacturer Hugel Aesthetics.
The findings, presented during the November 5-8 meeting in San Diego, included efficacy, onset of action, and patient-reported outcomes from the BLESS clinical development program.
Letybo is a botulinum toxin type A product approved by the US Food and Drug Administration (FDA) for the temporary improvement of moderate to severe glabellar lines in adults.
BLESS III Trial Results and Patient-Reported Outcomes
In the randomized, double-blind, placebo-controlled Phase 3 BLESS III study, 64.7% of Letybo-treated patients achieved the primary improvement endpoint at week 4, compared with 0% in the placebo group. The median time to improvement was 3 days, and investigators reported no serious treatment-related adverse events.
Michael H. Gold, MD, presented additional post hoc analyses evaluating women aged 35 to 50 years. Up to 87.4% achieved improvement by week 2, while 73.6% had no visible glabellar lines at maximum frown by week 4, corresponding to a score of 0 on the Glabellar Line Scale.
A separate pooled analysis involving 1,272 participants across three BLESS trials evaluated patient-reported outcomes. According to Hugel, the findings showed improvements in quality of life, emotional well-being, and treatment satisfaction compared with placebo.
The company also highlighted its expanding US presence and interest in Korean aesthetic approaches, commonly referred to as K-Aesthetics.
Source
Hugel. Hugel Aesthetics showcases growing U.S. presence, clinical innovation and K-Aesthetic leadership at 2026 ASDS Annual Meeting. PR Newswire. Published November 18, 2026. Accessed November 18, 2026. Read press release